AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05878535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
Study NCT06455475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Derm-Maxx
Description: Derm-Maxx™ Dermal Matrix is an acellular human dermis graft sterilized using the Tutoplast® Tissue Sterilization Process.
Study NCT06568757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wet Cupping
Description: Wet cupping therapy will be applied once using disposable plastic vacuum cups to a total of 4 areas, which are recommended areas for headaches; cervical spine C7 (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupuncture point) and suboccipital region (FengFu DU-16 acupuncture point).
Study NCT06568757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No treatment will be applied to individuals and the routine medical treatment program will continue.
Study NCT06454955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga] B7H3 Affibody-BCH
Description: An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
Study NCT05471141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognition ECHO
Description: Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
Study NCT05716516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol
Description: Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
Study NCT05514327 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultra-fraction radiotherapy
Description: the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
Study NCT06402058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMSB01
Description: Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
Study NCT03881748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Description: Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.
Study NCT03881748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied.
Study NCT04431960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blackcurrant (BC) extract
Description: A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
Study NCT04431960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blackcurrant (BC) extract
Description: A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
Study NCT05940558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist
Study NCT05712603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FIB4-score
Description: A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
Study NCT05712603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vibration controlled transient elastography
Description: VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
Study NCT05712603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enhanced Liver Fibrosis test
Description: The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
Study NCT06647862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IV infusion
Study NCT06647862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: subcutaneous injection
Study NCT06647862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: subcutaneous injection
Study NCT06647862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT06650371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl infusion
Description: opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
Study NCT06650371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamedomedine and ketamine infusion
Description: Analgesia will be offered by syringe containing ketamine and Dexmedetomidine in induction and maintenance according to IBW.
Study NCT06650488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients will change from aspirin to clopidogrel (without loading dose)
Study NCT06650488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients will continue their existing aspirin.
Study NCT06653595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programme to Support Breastfeeding
Description: The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
Study NCT06652945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Description: Uterine artery embolization under fluoroscopy
Study NCT06264011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salaat
Description: While Muslims perform mandatory salaat (prayer) 5 times daily, the Duha salaat is an optional daily prayer consisting of 4 cycles of standing, bowing, standing again, prostrating, kneeling, and prostrating again. Research has shown that salaat may influence physiological relaxation.
Study NCT06264011 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Participants will count while mimicking the movements of the Duhaa salaat. This is a no-prayer condition in which the recitation of Qur'an is omitted for the sake of comparison.
Study NCT06244134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided autologous blood injection
Description: guided
Study NCT06244134 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non guided autologous blood injection
Description: non guided
Study NCT05749900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin
Description: Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
Study NCT06538155 — intervention group
Intervention type: DEVICE
Intervention: Wearable device
Description: Wearable devices that are preferentially Food and Drug Administration (FDA) and/or Conformité Européenne (CE) marked
Study NCT06538155 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary resuscitation
Description: Cardiopulmonary resuscitation
Study NCT06538155 — intervention group
Intervention type: OTHER
Intervention: CT scan, TEE exam, or chest X ray
Description: Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray
Study NCT06003283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV rituximab
Study NCT06003283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV rituximab
Study NCT06493058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: The babies in the study group were given the supine, right lateral and left lateral positions (12×1), which are used in nursing care practices in the clinic after extubation, in addition to the supine, right lateral and left lateral positions (12×1), the prone position was given twice a day for 2×2 hours twice a day within 48 hours after extubation, with the head on the midline of the neck and the head facing to the right or left side.
Study NCT05594719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shorter-wavelength dominant light
Description: Shorter-wavelength dominant light
Study NCT05594719 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light similar to the solar spectrum proportion
Description: Light similar to the solar spectrum proportion with no specific wavelength dominant
Study NCT05594719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Longer-wavelength dominant light
Description: Longer-wavelength dominant light
Study NCT04668768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
Study NCT06402058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rejuran®
Description: Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
Study NCT04909086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical Therapy
Description: Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
Study NCT04909086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain
Description: Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
Study NCT04909086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain
Description: Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
Study NCT05220306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of vital signs
Description: The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
Study NCT04880096 — intervention group
Intervention type: OTHER
Intervention: eDOL
Description: e-health tool (mobile app for patients and web platform for caregivers in pain clinics)
Study NCT04822701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 767551 intravenous
Description: BI 767551 intravenous
Study NCT05441735 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: APP
Description: APP as an instructional tool for visiting health education
Study NCT04822701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 767551 inhaled
Description: BI 767551 inhaled
Study NCT04822701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous
Description: Placebo intravenous
Study NCT04822701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo intravenous
Description: Placebo intravenous
Study NCT04822701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhaled
Description: Placebo inhaled
Study NCT04822701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhaled
Description: Placebo inhaled
Study NCT06413199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyper Training
Description: Experimental group will perform 2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 Reps with 90 seconds rest between sets. 1.5 second concentric and 1.5 second eccentric contraction of bench press, The elbows had to be fully locked out to be counted as a repetition.
Study NCT06413199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 Repetition maximum training group
Description: 2 training session per week for 8 weeks, 1 set of 10 unloaded repetitions in arms as a warm-up, 1 Repetition maximum training group consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts, the load was progressively increased each attempt to try to reach or exceed their previous 1 repetition maximum.
Study NCT04654533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COSC
Description: COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, \& Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study.
Study NCT04940845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20090-2
Description: Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
Study NCT04940845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia
Description: Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
Study NCT04270838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG
Description: Single dose of ChAdOx2 RabG at different concentrations: 1x10\^10 and 5x10\^10
Study NCT04270838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Rabies Vaccine
Description: A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
Study NCT05703191 — intervention group
Intervention type: DEVICE
Intervention: Nitric Oxide Generator and Delivery System
Description: Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
Study NCT05090891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCBG000928 will be administered QD orally.
Study NCT05090891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo will be administered QD orally
Study NCT05090891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered QD orally
Study NCT06002945 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
Study NCT05898126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renin-guided hemodynamic management
Description: If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
Study NCT05898126 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Standard of care
Study NCT05939999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Elastic tape (ET)
Description: The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
Study NCT05939999 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham (SH)
Description: The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
Study NCT05094648 — intervention group
Intervention type: OTHER
Intervention: high flow nasal therapy
Description: effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive
Study NCT06363734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib plus Dalpiciclib
Description: osimertinib 80mg daily plus dalpiciclib 125mg daily for 21 days followed by 7 days off in each 28-day treatment cycle
Study NCT06206161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indicated Prevention, Clinical Staff
Description: Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
Study NCT06206161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indicated Prevention, Clinical Staff
Description: Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
Study NCT06206161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Selective Prevention
Description: Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use).
Study NCT06206161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Paraprofessional Workforce
Description: Brief interventions delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
Study NCT05375591 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: First nodule detection CT scans as per eligibility criteria will be used as input into in-house software to extract multiple radiomic features and used to develop a machine learning based classifier to differentiate nodule aetiology. Scans will also be used as input in to a deep learning/convolutional neural network models to perform automated imaging classification.
Study NCT05413161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADL-018
Description: 150 mg/mL, Solution for injection in PFS
Study NCT05413161 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed XOLAIR
Description: 150 mg/mL, Solution for injection in PFS
Study NCT05413161 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Approved XOLAIR
Description: 150 mg/mL, Solution for injection in PFS